TUG1 and cancer: For studies evaluating OS in different type of cancer, the results suggested that promoted lncRNA TUG1 levels could estimate worse outcome in bladder cancer (HR = 2.98, 95% CI: 1.84–4.83, P < 0.0001) and other system cancer (HR = 2.63, 95% CI: 1.42–4.87, P = 0.002), but not respiratory system cancer (HR = 0.93, 95% CI: 0.30–2.82, P = 0.895), (Figure 3A).